A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
PHASE1Not yet recruitingINTERVENTIONAL
Enrollment
37
Participants
Timeline
Start Date
August 31, 2025
Primary Completion Date
June 30, 2026
Study Completion Date
February 28, 2027
Conditions
NHLCutaneous T Cell LymphomaPeripheral T-cell Lymphoma